Translate page

× To share and enhance best practice management of CML, experts and interested clinicians can discuss difficult or interesting CML cases here. Clinicians submit a brief history of the patient and the case for discussion (no more than 200 words) by posting it in this forum ("+ NEW TOPIC" button below). Please include the country of origin.

Each clinical case will be forwarded to the expert clinical panel for a brief independent response. Consideration should be given to patient confidentiality. Details that are not critical to the case can be changed to preserve anonymity. Please consider including your email with the case. This will not be posted on the website, but is useful should further details be requested by the moderator.

As a full clinical history is necessary for accurate comment, cases and comments on the Forum are ONLY ACCEPTED FROM CLINICIANS. If individual patients have a specific question we encourage them to contact their healthcare provider. General questions can be emailed to info@cml-foundation.org.

DISCLAIMER: The iCMLf does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this Forum is solely at your own risk.

Poor CML response to imatinib, dasatinib

  • Michele Baccarani
  • Michele Baccarani's Avatar
9 years 3 months ago #273 by Michele Baccarani
Replied by Michele Baccarani on topic Re: Poor CML response to imatinib, dasatinib
I believe that in any resistant, and particularly unusual, case, it is very important to know more. More tests require more money, but never as much as a wrong treatment decision. And forgetting money, a wrong treatment decision is not good for the patient. Therefore I confirm that a bone marrow examination, cytology, histopathology, and karyotype, would help. And I confirm that in the meantime I would test again imatinib, full dose.

Regards, Michele Baccarani
  • johnmgoldman
  • johnmgoldman's Avatar
9 years 3 months ago #275 by johnmgoldman
Replied by johnmgoldman on topic Re: Poor CML response to imatinib, dasatinib
I would probably repeat all relevant examinations, then switch to nilotinib. Ponatinb can indeed also be considered. SCT is third option, as you suggest

John Goldman













bn
Moderators: Melissa Davis-Bishop